# Remogliflozin Etabonate Effect on Primary Biliary Cholangitis

> **NIH NIH R43** · AVOLYNT, INC. · 2021 · $226,375

## Abstract

Project Summary
Primary biliary cholangitis (PBC) is a serious, chronic cholestatic liver disease characterized by a
progressive, autoimmune-based destruction of the bile duct, and the eventual onset of cirrhosis and its
complications. There are limited FDA-approved drugs for the management of PBC, but in many cases
liver transplantation is required and offers the only chance for a complete cure. Therefore, effective
treatments are urgently needed to treat PBC and to delay time to liver transplantation and to improve
the quality of life for PBC patients. With that goal in mind, a novel approach for treating PBC is
described below. These developments are based on the observation that remogliflozin etabonate, an
SGLT2 inhibitor with unique differentiating properties from other SGLT2 inhibitors, prevents the
progression of PBC disease pathology in a murine model of liver damage. Based on our compelling
preliminary data, this Phase I confirmation of proof-of-concept study will demonstrate that
remogliflozin etabonate is a potential therapy for PBC. We will achieve these goals by the following
Aims: 1) Evaluate the role of remogliflozin and other SGLT inhibitors in liver cells in vitro. SGLTs
are expressed in biliary ducts and inhibition of SGLTs causes increased biliary flow; and 2) Confirm in
vivo our earlier observation that remogliflozin etabonate can prevent or reverse PBC progression using
a well-accepted murine model of PBC.

## Key facts

- **NIH application ID:** 10323592
- **Project number:** 1R43DK130691-01
- **Recipient organization:** AVOLYNT, INC.
- **Principal Investigator:** william O wilkison
- **Activity code:** R43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $226,375
- **Award type:** 1
- **Project period:** 2021-09-15 → 2022-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10323592

## Citation

> US National Institutes of Health, RePORTER application 10323592, Remogliflozin Etabonate Effect on Primary Biliary Cholangitis (1R43DK130691-01). Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/grant/nih/10323592. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*